This is Michael Brady Lynch, lead trial attorney for The Michael Brady Lynch Firm.

Today I am pleased to announce that I am accepting Nexium bone fracture and Propecia sexual dysfunction and prostate cancer cases. I feel the overwhelming scientific evidence that both these drugs harm the public to such a degree to warrant removal from the market mandates my active representation on behalf of American consumers.

Nexium is a proton pump inhibitor manufactured by AstraZeneca and is available only to adults by way of prescription. The FDA weighed in on the dangers of bone fractures associated with Nexium usage in May 2010 and again in March 2011. Nexium is a blockbuster drug and AstraZeneca reaps billions every year from the sale of Nexium.  However, numerous studies have linked Nexium usage, especially usage over 1 year, to a wide array of bone fractures at an alarming rate.

 

I am scheduled to speak at the upcoming AAJ Winter Convention at Litigation at Sunrise on Nexium and bone fractures. I also Chair the AAJ Nexium Litigation Group and will chair a Nexium Litigation Group meeting in Phoenix Arizona at the AAJ Winter Convention where I expect over 60 lawyers in attendance. I am excited to be at the forefront of Nexium bone fracture litigation and am accepting both direct client solicitations and referrals from attorneys and attorney groups.

                                                                                                                                                                                                                    The hidden story of Nexium is the connection with birth defects that have mostly been flying under the radar with little or no exposure in the media and medical community. Prenatal (before birth) use of Nexium and other PPIs by pregnant women have been linked to a doubled risk of cardiac birth defects in their babies. Researchers from the University of Pennsylvania analyzed data from The Health Improvement Network (THIN) to determine that there may be a correlation between PPI use during the first trimester and congenital heart defects.

I have also previously written about the dangers of Propecia. Research shows that use of Propecia may lead to increased risk of high-grade prostate cancer, as well as sexual issues including erectile dysfunction. The FDA weighed in on these disturbing findings in June and July 2011 and issued new warnings over Propecia and prostate cancer. Propecia’s association with long-term, and even permanent, sexual dysfunction were detailed in a study in the Journal of Sexual Medicine.

                                                                                                                                                                                                                 Propecia is a drug that has been on the market for over a decade, all the while unknowing American consumers have been placing themselves at risk for erectile dysfunction and prostate cancer.  The new findings this summer by the FDA linking Propecia to prostate cancer makes Propecia’s risk-benefit an absolute no-win for American consumers.